Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing immuno-oncology jargon, pipeline milestones, and dilution risks inside Werewolf Therapeutics’ SEC filings can feel like decoding lab notes. The company’s 10-K alone runs hundreds of pages on conditional IL-12 and IL-2 programs, cash runway assumptions, and collaboration clauses—details that are critical yet hard to spot.
Stock Titan’s AI-powered analysis turns that problem into a two-minute read. Our engine combs every Werewolf Therapeutics quarterly earnings report 10-Q filing, flags trial-phase updates, and highlights changes in R&D spend. Need to track management confidence? Real-time alerts surface Werewolf Therapeutics insider trading Form 4 transactions the moment they hit EDGAR. Curious about sudden stock moves? We translate each Werewolf Therapeutics 8-K material event into plain English, clarifying data-release language and financing announcements.
The result is one hub covering every document—from the annual report 10-K simplified for fast risk-factor review to proxy statement executive compensation details and executive stock transactions Form 4. Investors use these insights to monitor cash burn, compare quarter-over-quarter pipeline progress, and gauge insider sentiment before material catalysts. Stop wading through dense PDFs; understand Werewolf Therapeutics SEC filings explained simply with AI that keeps pace with biotech’s rapid developments.
Werewolf Therapeutics director Luke Evnin reported a series of open-market sales of the company’s common stock under a pre-established Rule 10b5-1 trading plan dated September 24, 2025. On November 18, 2025, affiliated funds sold 33,776 shares at a weighted average price of $0.93, leaving 3,482,104 shares beneficially owned indirectly. On November 19, 2025, they sold 42,566 shares at a weighted average price of $0.94, leaving 3,439,538 shares. On November 20, 2025, they sold 26,411 shares at a weighted average price of $0.89, leaving 3,413,127 shares. The filing explains that the shares are held through various MPM-affiliated entities and that Evnin disclaims beneficial ownership beyond his pecuniary interest.
Werewolf Therapeutics, Inc. (HOWL)
The group sold 52,627 shares on November 18, 2025 at a weighted average price of $0.93, 66,324 shares on November 19, 2025 at a weighted average price of $0.94, and 41,152 shares on November 20, 2025 at a weighted average price of $0.89. After these sales, they reported indirect beneficial ownership of 5,321,436 shares held across several MPM-managed entities, including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Oncology Innovations Fund and UBS Oncology Impact Fund, with each reporting person disclaiming beneficial ownership beyond its pecuniary interest.
Werewolf Therapeutics, Inc. (HOWL) reported insider transactions by entities affiliated with MPM BioImpact LLC, which is identified as a director and 10% owner. Over three days, from 11/18/2025 to 11/20/2025, these reporting persons sold a total of 160,103 shares of common stock in open-market transactions. The weighted average sale prices were around $0.93 on 11/18, $0.94 on 11/19, and $0.89 on 11/20, with detailed price ranges provided for each day. After these sales, the reporting group continued to beneficially own 5,321,436 shares of Werewolf Therapeutics indirectly through multiple affiliated investment vehicles. The filing notes that the trades were executed under a Rule 10b5-1 trading plan dated September 24, 2025.
Werewolf Therapeutics (HOWL) director Luke Evnin reported a series of planned insider stock sales under a Rule 10b5-1 trading plan. On 11/13/2025, affiliated MPM entities sold 58,372 shares of common stock at a weighted average price of $0.98. On 11/14/2025, they sold 39,560 shares at a weighted average price of $0.93, and on 11/17/2025, they sold 36,621 shares at a weighted average price of $0.95. After these transactions, Evnin reported 3,515,880 shares of HOWL common stock beneficially owned indirectly through various MPM investment vehicles. The filing notes that prices are reported as weighted averages for multiple trades within specified price ranges.
Werewolf Therapeutics, Inc. (HOWL) reported insider stock sales by an affiliated director and 10% owner. Investment entities associated with MPM BioImpact LLC filed a Form 4 showing automatic sales of common stock under a Rule 10b5-1 trading plan dated September 24, 2025. On November 13, 2025, they sold 90,951 shares at a weighted average price of $0.98 per share, followed by 61,640 shares at $0.93 on November 14 and 57,061 shares at $0.95 on November 17. After these transactions, the group reported indirect beneficial ownership of 5,481,539 shares held across several MPM-managed funds, while disclaiming beneficial ownership beyond their economic interest. This filing is one of two identical submissions due to limits on the number of reporting persons.
Werewolf Therapeutics, Inc. (HOWL)
On November 13, 2025, the reporting group sold 90,951 shares at a weighted average price of $0.98. On November 14, 2025, they sold 61,640 shares at a weighted average price of $0.93, and on November 17, 2025, they sold 57,061 shares at a weighted average price of $0.95. Each day’s trades occurred across multiple prices within disclosed ranges.
After these transactions, the group reports indirect beneficial ownership of 5,481,539 Werewolf shares held through several affiliated investment vehicles, including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Oncology Innovations Fund, and UBS Oncology Impact Fund.
Werewolf Therapeutics (HOWL) — Form 4 insider activity: Director Luke Evnin reported open‑market sales of company common stock executed under a Rule 10b5‑1 trading plan dated September 24, 2025. Sales occurred on four dates: 11/07/2025 (43,950 shares at a weighted average price of $1.11), 11/10/2025 (31,172 at $1.18), 11/11/2025 (35,818 at $1.14), and 11/12/2025 (26,101 at $1.09).
Following these transactions, the reported indirect beneficial holdings were updated to 3,743,524; 3,712,352; 3,676,534; and 3,650,433 shares, respectively. The holdings are indirect through affiliated entities (including AM LLC, BV 2014, BV 2014(B), AM BV2014, and MPM OIF), with a stated disclaimer of beneficial ownership beyond pecuniary interest.
Werewolf Therapeutics (HOWL): affiliated reporting persons led by MPM entities, identified as a director and 10% owner, reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. Sales occurred on November 7–12, 2025 across four days totaling 213,529 shares.
Disclosed transactions: 68,480 shares on 11/07 at a weighted average price of $1.11; 48,570 on 11/10 at $1.18; 55,810 on 11/11 at $1.14; and 40,669 on 11/12 at $1.09. Following these trades, the group reported 5,691,191 shares beneficially owned, held indirectly across multiple MPM-managed entities. Price ranges for the weighted averages were provided for each day, and the filing notes it is one of two identical filings due to reporting person limits.
Werewolf Therapeutics (HOWL): A director and 10% owner affiliated with MPM entities reported open‑market sales totaling 213,529 shares across 11/07–11/12/2025 under a Rule 10b5‑1 plan dated September 24, 2025. Weighted average prices by day were $1.11, $1.18, $1.14 and $1.09, with disclosed trade ranges spanning $1.065 to $1.21. Following these transactions, indirect beneficial ownership was 5,691,191 shares.
Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales totaling 155,885 shares on November 4–6, 2025 under a Rule 10b5‑1 trading plan established on September 24, 2025.
Weighted‑average sale prices were $1.22 on Nov 4 (range $1.17–$1.30), $1.22 on Nov 5 (range $1.19–$1.25), and $1.21 on Nov 6 (range $1.185–$1.27). Following these transactions, indirect beneficial holdings were 3,787,474 shares, held across multiple MPM‑affiliated entities. The filing notes the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
FAQ
What is the current stock price of Werewolf Therapeutics (HOWL)?
What is the market cap of Werewolf Therapeutics (HOWL)?
